Commodore Capital LP
Filing Date
Global Rank
#1,475
/ 8,700
▲ 178
Top Industry
Biotechnology
82.5%
Period ended 2 months ago
Filed Aug 14, 2026 · 30d
23 quarters · since Dec 2020
Portfolio Concentration
33 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
13.5%
+3.0 pts
Top 5
46.0%
+5.7 pts
Top 10
68.7%
+4.8 pts
HHI
630
Diversified+100
Portfolio Trend
23 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.4% | $1,655,970,921 |
| Financial Services | 0.6% | $10,670,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
6 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| EYPT | EyePoint, Inc. | +1,775,000 | 4,600,000 | $65,780,000 | |
| RLMD | Relmada Therapeutics, Inc. | +791,099 | 1,425,000 | $9,861,000 | |
| ANTX | AN2 Therapeutics, Inc. | +599,967 | 2,933,680 | $14,199,011 | |
| AVTX | Avalo Therapeutics, Inc. | +535,319 | 1,018,319 | $18,818,535 | |
| ASMB | Assembly Biosciences, Inc. | +415,000 | 1,415,000 | $38,884,200 | |
| COGT | Cogent Biosciences, Inc. | +161,993 | 3,050,000 | $118,035,000 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
9 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| RLAY | Relay Therapeutics, Inc. | −5,000,000 | 12,000,000 | $224,520,000 | |
| SABS | SAB Biotherapeutics, Inc. | −1,531,500 | 2,870,000 | $11,193,000 | |
| CLDX | Celldex Therapeutics, Inc. | −1,346,616 | 1,350,000 | $50,233,500 | |
| ALKS | Alkermes plc. | −1,200,000 | 3,000,000 | $157,200,000 | |
| SYRE | Spyre Therapeutics, Inc. | −1,065,594 | 846,786 | $75,177,661 | |
| — | −733,600 | 100,000 | $0 | ||
| TYRA | Tyra Biosciences, Inc. | −600,000 | 1,875,000 | $59,887,500 | |
| KYMR | Kymera Therapeutics, Inc. | −500,000 | 250,000 | $28,667,500 | |
| PHVS | Pharvaris N.V. | −493,970 | 1,425,000 | $49,276,500 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
5 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| TNGX | Tango Therapeutics, Inc. | 2,250,000 | $70,335,000 | |
| EDIT | Editas Medicine, Inc. | 8,889,000 | $28,800,360 | |
| IFRX | InflaRx N.V. | 7,300,000 | $16,352,000 | |
| RACC | Research Alliance Corp III | 500,000 | $5,350,000 | |
| VTGN | Vistagen Therapeutics, Inc. | 2,788,620 | $641,382 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
8 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| ERAS | Erasca, Inc. | 3,175,000 | $51,371,500 | |
| XENE | Xenon Pharmaceuticals Inc. | 825,000 | $47,973,750 | |
| NRIX | Nurix Therapeutics, Inc. | 2,275,000 | $35,262,500 | |
| CRVS | Corvus Pharmaceuticals, Inc. | 2,258,735 | $33,045,293 | |
| OCUL | Ocular Therapeutix, Inc | 2,575,000 | $21,810,250 | |
| PALI | Palisade Bio, Inc. | 7,181,062 | $12,566,858 | |
| KPTI | Karyopharm Therapeutics Inc. | 1,950,000 | $10,861,500 | |
| — | 652,432 | $0 | ||
| No positions match the current search. | ||||
33 tracked positions ·
$1,666,640,921 total
· filing declares
33 positions · $1,678,964,770
· as of Jun 30, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| RLAY |
Relay Therapeutics, Inc.
Healthcare
|
Reduced | 12,000,000 | $224,520,000 | 13.47% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Held | 3,275,000 | $166,206,250 | 9.97% | |
| ALKS |
Alkermes plc.
Healthcare
|
Reduced | 3,000,000 | $157,200,000 | 9.43% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Added | 3,050,000 | $118,035,000 | 7.08% | |
| AMLX |
Amylyx Pharmaceuticals, Inc.
Healthcare
|
Held | 5,650,000 | $101,474,000 | 6.09% | |
| DFTX |
Definium Therapeutics, Inc.
Healthcare
|
Held | 2,000,000 | $94,080,000 | 5.64% | |
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
Reduced | 846,786 | $75,177,661 | 4.51% | |
| ANRO |
Alto Neuroscience, Inc.
Healthcare
|
Held | 2,723,196 | $71,865,142 | 4.31% | |
| TNGX |
Tango Therapeutics, Inc.
Healthcare
|
NEW | 2,250,000 | $70,335,000 | 4.22% | |
| EYPT |
EyePoint, Inc.
Healthcare
|
Added | 4,600,000 | $65,780,000 | 3.95% | |
| TYRA |
Tyra Biosciences, Inc.
Healthcare
|
Reduced | 1,875,000 | $59,887,500 | 3.59% | |
| DMRA |
Damora Therapeutics, Inc.
Healthcare
|
Held | 1,939,000 | $50,433,390 | 3.03% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Reduced | 1,350,000 | $50,233,500 | 3.01% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
Reduced | 1,425,000 | $49,276,500 | 2.96% | |
| LBRX |
Lb Pharmaceuticals Inc
Healthcare
|
Held | 1,500,000 | $48,682,500 | 2.92% | |
| ASMB |
Assembly Biosciences, Inc.
Healthcare
|
Added | 1,415,000 | $38,884,200 | 2.33% | |
| EDIT |
Editas Medicine, Inc.
Healthcare
|
NEW | 8,889,000 | $28,800,360 | 1.73% | |
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Reduced | 250,000 | $28,667,500 | 1.72% | |
| CATX |
Perspective Therapeutics, Inc.
Healthcare
|
Held | 6,336,782 | $21,608,426 | 1.30% | |
| IPSC |
Century Therapeutics, Inc.
Healthcare
|
Held | 8,695,652 | $21,304,347 | 1.28% | |
| ZURA |
Zura Bio Ltd
Healthcare
|
Held | 3,250,000 | $19,175,000 | 1.15% | |
| AVTX |
Avalo Therapeutics, Inc.
Healthcare
|
Added | 1,018,319 | $18,818,535 | 1.13% | |
| IFRX |
InflaRx N.V.
Healthcare
|
NEW | 7,300,000 | $16,352,000 | 0.98% | |
| ANTX |
AN2 Therapeutics, Inc.
Healthcare
|
Added | 2,933,680 | $14,199,011 | 0.85% | |
| SABS |
SAB Biotherapeutics, Inc.
Healthcare
|
Reduced | 2,870,000 | $11,193,000 | 0.67% | |
| IKT |
Inhibikase Therapeutics, Inc.
Healthcare
|
Held | 5,397,488 | $10,956,900 | 0.66% | |
| RLMD |
Relmada Therapeutics, Inc.
Healthcare
|
Added | 1,425,000 | $9,861,000 | 0.59% | |
| PEPG |
PepGen Inc.
Healthcare
|
Held | 4,475,000 | $8,055,000 | 0.48% | |
| RACC |
Research Alliance Corp III
Financial Services
|
NEW | 500,000 | $5,350,000 | 0.32% | |
| HLXC |
Helix Acquisition Corp. III
Financial Services
|
Held | 500,000 | $5,320,000 | 0.32% | |
| LONA |
LeonaBio, Inc.
Healthcare
|
Held | 464,398 | $4,267,817 | 0.26% | |
| VTGN |
Vistagen Therapeutics, Inc.
Healthcare
|
NEW | 2,788,620 | $641,382 | 0.04% | |
|
|
Reduced | 100,000 | $0 | 0.00% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.